CLAIMS

1. A pharmaceutical formulation comprising:

(a) about 150 mg/ml of an isolated anti-Factor XI (FXI) and/or anti-activated Factor XI (FXIa) antibody or antigen-binding fragment thereof, whrein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising complementary determining regions HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 29: and a light chain variable region (VL) comprising complementary determining regions LCDR1, LCDR2, LCDR3 in SEQ ID NO: 39;

(b) about 20 mM L-histidine buffer;

(c) about 220 mM sucrose; and

(d) about 0.04% polysorbate 20,

at about pH5.5.

2. The pharmaceutical formulation of claim 1, wherein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises:

i. a heavy chain variable region CDR1 of SEQ ID NO: 23; a heavy chain variable region CDR2 of SEQ ID NO: 24; a heavy chain variable region CDR3 of SEQ ID NO: 25; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 34; and a light chain variable region CDR3 of SEQ ID NO: 35;

ii. a heavy chain variable region CDR1 of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 27; a heavy chain variable region CDR3 of SEQ ID NO: 28; a light chain variable region CDR1 of SEQ ID NO: 36; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 38;

iii. a heavy chain variable region CDR1 of SEQ ID NO: 43; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 45; a light chain variable region CDR1 of SEQ ID NO: 47; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 15; or

iv. a heavy chain variable region CDR1 of SEQ ID NO: 46; a heavy chain variable region CDR2 of SEQ ID NO: 4; a heavy chain variable region CDR3 of SEQ ID NO: 5; a light

chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 14; and a light chain variable region CDR3 of SEQ ID NO: 15.

3. An intravenous formulation comprising:

(a) an isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof at a concentration between 1.20 mg/mL and 1.80 mg/mL, whrein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising complementary determining regions HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 29: and a light chain variable region (VL) comprising complementary determining regions LCDR1, LCDR2, LCDR3 in SEQ ID NO: 39;

(b) about 0.20 mM histidine buffer;

(c) about 2.20 mM sucrose;

(d) about 0.0004% polysorbate 20, and

(e) a diluent solution comprising a second sugar and water, wherein the second sugar is dextrose at a concentration about 5% (v/v).

at about pH 5.5.

4. The intravenous formulation of claim 3, wherein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises:

i. a heavy chain variable region CDR1 of SEQ ID NO: 23; a heavy chain variable region CDR2 of SEQ ID NO: 24; a heavy chain variable region CDR3 of SEQ ID NO: 25; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 34; and a light chain variable region CDR3 of SEQ ID NO: 35;

ii. a heavy chain variable region CDR1 of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 27; a heavy chain variable region CDR3 of SEQ ID NO: 28; a light chain variable region CDR1 of SEQ ID NO: 36; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 38;

iii. a heavy chain variable region CDR1 of SEQ ID NO: 43; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 45; a light chain variable region CDR1 of SEQ ID NO: 47; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 15; or

iv. a heavy chain variable region CDR1 of SEQ ID NO: 46; a heavy chain variable region CDR2 of SEQ ID NO: 4; a heavy chain variable region CDR3 of SEQ ID NO: 5; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 14; and a light chain variable region CDR3 of SEQ ID NO: 15.

5. The intravenous formulation of claim 3, wherein the therapeutically effective amount of an isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof is at an amount of about 1.5 mg.

6. The pharmaceutical formulation of claim 1, wherein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises a VH with at least 90% identity to SEQ ID NO: 29 and a VL with at least 90% identity to SEQ ID NO: 39.

7. The pharmaceutical formulation of claim 1, wherein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises a VH of SEQ NO: 29 and a VL of SEQ ID NO: 39.

8. The pharmaceutical formulation of claim 1, wherein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises a heavy chain of SEQ ID NO: 31 or a heavy chain with at least 90% identity thereto, and a light chain of SEQ ID NO: 41 or a light chain with at least 90% identity thereto.

9. The pharmaceutical formulation of claim 1, wherein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises a heavy chain of SEQ ID NO: 31 and a light chain of SEQ ID NO: 41.

10. The intravenous formulation of claim 3, wherein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises a VH with at least 90% identity to SEQ ID NO: 29 and a VL with at least 90% identity to SEQ ID NO: 39.

11. The intravenous formulation of claim 3, wherein the isolated anti-FXI and/or anti-FXIa antibody or antigen-binding fragment thereof comprises a VH of SEQ NO: 29 and a VL of SEQ ID NOs: 39.

12. The intravenous formulation of claim 3, wherein the isolated anti-FXI and/or anti-FXIa antibody comprises a heavy chain of SEQ ID NO: 31 or a heavy chain with at least 90% identity thereto, and a light chain of SEQ ID NO: 41 or a light chain with at least 90% identity thereto.

13. The intravenous formulation of claim 3, wherein the isolated anti-FXI and/or anti-FXIa antibody comprises a heavy chain of SEQ ID NO: 31 and a light chain of SEQ ID NO: 41.